Purpose: Endovascular thrombectomy (EVT) treatment for acute ischemic stroke is now recommended as a standard of care. However, implementing EVT in routine clinical practice poses many challenges, even in countries with advanced health-care systems.
Introduction
Endovascular thrombectomy (EVT) for the treatment of acute ischemic stroke caused by proximal intracranial large vessel occlusion (LVO) involving the anterior cerebral circulation has become the standard of care in many countries, including Canada. 1, 2 The efficacy of EVT in randomized control trials can largely be ascribed to improved stent retriever devices, selection criteria of suitable patients based on strict clinical and imaging criteria, and efficient workflow practices. 3 Determining the effectiveness of this complex interventional treatment in routine clinical practice is the next question to be addressed; indeed, evaluation of local EVT experiences may be required by health-care jurisdictions to inform decisions about implementation of the therapy.
The purpose of the current study was to examine the effectiveness of EVT in our institution, which was one of the 22 centers participating in the multinational stroke efficacy ESCAPE (Endovascular Treatment for Small Core and Proximal Occlusion Ischemic Stroke) trial. 4 Our hypothesis was that the ESCAPE trial methods and outcomes could be replicated in routine clinical practice at a single center.
Methods
All patients undergoing EVT for anterior cerebral circulation LVO at a small tertiary care institution covering a population of approximately 900 000, from December 2011 to July 2017, were identified from our prospective stroke registry. 5 Data for this study were derived from the registry and from review of the patients' health records and imaging files stored on PACS (picture archiving and communication system). All EVT-treated patients had symptoms and signs of acute ischemic stroke and LVO on single-phase computed tomography angiography (CTA) performed at our institution. Intravenous tissue plasminogen activator (tPA) was administered as soon as possible to patients who were eligible. All EVT procedures were performed by a group of 5 fellowship trained interventional neuroradiologists with at least 5 years of experience. Endovascular thrombectomy was performed using second-generation Solitaire (Medtronic, Minneapolis, Minnesota) retrievable stent devices delivered via the neuroradiologist's choice of access system. The technique of EVT remained unchanged during the duration of this study.
In addition to CTA, our acute stroke imaging protocol included plain head computed tomography (CT) and computed tomography perfusion. The Alberta Stroke Program Early CT (ASPECT) score (details available at www.aspectsinstroke. com) was used to assess the CT. Computed tomography perfusion was used to exclude patients from EVT when the cerebral blood flow and cerebral blood volume maps showed matched deficits indicating the absence of salvageable brain tissue. 6 Postprocedure recanalization was quantified using the modified Treatment in Cerebral Infarction (mTICI) score. 7 The workflow in our institution followed that from the ESCAPE trial as were part of the trail. The effectiveness of our EVT program was assessed by comparing the demographics, treatment timelines, and outcome parameters of our patients with those enrolled in ESCAPE trial. Statistical analysis was carried out using STATA V.13.0 software package. 8 Continuous variables were recoded as categorical variables for the purpose of analysis. Univariate and multivariate analyses of outcomes were done using Mantel-Haenszel tests and logistic regression, respectively. Chi-square tests and independent t tests were used where appropriate. A P value of .05 was considered significant. Table 1 compares the demographic, clinical, and imaging details of the 88 patients consecutively treated with EVT at our institution with those allocated to receive EVT in ESCAPE. Only 2 of these patients were included in the endovascular arm of ESCAPE trial. The median time from last seen normal to arrival was 87 minutes (range: 19-972 minutes). In our registry, 5 ischemic strokes are described using the Oxfordshire Community Stroke Project (OCSP) classification. 9 Our EVT cohort comprised 69% total anterior cerebral circulation strokes (OCSP TACS) and 24% partial anterior circulation strokes (OCSP PACS), which have median (interquartile range [IQR]) National Institutes of Health Stroke Severity Scores (NIHSS) of 18 (12-21) and 10 (7-15), respectively. 10 In the ESCAPE trial, the median (IQR) NIHSS for EVT-treated patients was 16 (13) (14) (15) (16) (17) (18) (19) (20) . Compared with the ESCAPE trial cohort, more of our patients (86% vs 68% in ESCAPE, P ¼ .002) had occlusion of the first segment of the middle cerebral artery (M1) and fewer had occlusion of the distal internal carotid artery; otherwise, the cohorts were similar. There was no significant difference in the proportion of patients receiving intravenous tPA in our study compared to ESCAPE, 72% versus 73% respectively (P ¼ .86). Table 2 compares the recanalization rate and the 90-day clinical status available in 75 patients treated with EVT at our institution with those allocated to receive EVT in ESCAPE. Angiographic outcomes of TICI 2b/3 results were similar (P ¼ .24) between our results (79%) and that from ESCAPE trial (72%). The case fatality was significantly higher among the patients treated at our institution (24% vs 10% in ESCAPE trial, P ¼ .004). Table 3 shows association of 90-day mRS with available angiographic and clinical characteristics, including successful recanalization, presence of atrial fibrillation, ipsilateral carotid stenosis greater than 50%, and total duration of EVT measured as time between femoral puncture and femoral closure. There was a trend toward patients with more severe stroke resulting in poor neurological outcome (P ¼ .052). The 5 interventional neuroradiologists performed 11%, 11%, 35%, 24%, and 19%, EVTs respectively. The recanalization rate (P ¼ .80) and 90day mRS (P ¼ .58) were not significantly different between the operators, although small number of individual operators was a limiting factor. Five (5.7%) patients had periprocedural minor technical complications that included carotid dissection, distal clot embolization, reocclusion of MCA, ophthalmic artery perforation, and puncture site hematoma and infection (1 patient each). One patient had major complications of symptomatic intracranial hemorrhage.
Results

Discussion
Our study demonstrated the effectiveness of EVT in routine clinical practice at a tertiary care center. The patient population, rate of successful recanalization, and functional independence in our study were similar to that seen in ESCAPE trial. We had lower proportion (8% vs 28%; P < .001) of patients with occlusion of carotid terminus and higher proportion (86% vs 68%; P ¼ .002) of patients with M1 occlusion.
Case fatality was significantly higher among our patients than in the ESCAPE trial. Exploratory univariate analyses showed that although no definitive explanation for this finding was found, higher proportion of death was associated with the presence of atrial fibrillation (P ¼ .032) and unsuccessful recanalization of mTICI <2b (P ¼ .006). Atrial fibrillation is known to be correlated with worse neurological outcome in patients with acute ischemic stroke. This association, although not entirely elucidated, has demonstrated that clot characteristics may differ in atrial fibrillation, as these patients demonstrate larger ischemic infarct volumes and greater frequency of hemorrhagic transformation. 11, 12 Unsuccessful recanalization of LVO has also been associated with poor neurological outcome. 4 Age and stroke severity, other known strong predictors of poststroke outcomes, a correlation previously shown at our institution, [13] [14] [15] [16] were comparable in our study relative to ESCAPE trial; however, a significantly greater proportion of case fatalities was demonstrated at our institution. In routine clinical practice, we may treat patients who would not have been included in clinical trials. For example, we treated 7 patients who were not functionally independent before their strokes. One of these patients died and the others showed no improvement.
Multiple effectiveness studies of EVT had showed case fatality rates in the range of 20% to 27.9%. [17] [18] [19] [20] [21] [22] The higher mortality rates in these studies may reflect the practice of providing comfort measures only for patients with severe deficits who do not respond to recanalization therapy. Early mortality after stroke, as seen in real-world studies, is most often attributed to the withdrawal or withholding of life-sustaining measures in light of poor prognosis and severe disabilities. Studies have shown that this practice is more reflective of patients' and caregivers' wishes and not the result of deviations from evidence-based practices. [23] [24] Furthermore, measures of functional independence and recanalization success in our experience were similar to those reported from hospitals in other countries with different healthcare systems, 18, 25, 26 providing further evidence of the effectiveness of EVT in routine clinical practice.
Limitations of the current study include the retrospective study design and relatively small patient sample. Although there was no statistical difference between the 5 interventional neuroradiologists with respect to clinical outcome, analysis is limited due to the small number of patients treated by individual operators, as well as more than one operator involved in a given procedure, which further limits analysis. The strengths are complete case ascertainment over a period of more than 5 years, providing data that can inform the process of improving the delivery of EVT locoregionally.
Conclusion
Our study provides further evidence of the effectiveness of EVT, in routine clinical practice in a small tertiary care center, for the treatment of acute ischemic stroke caused by proximal intracranial LVO involving the anterior cerebral circulation. This information may find application in planning the system changes needed to facilitate the wider use of this therapy.
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